S everal recent data have challenged the belief that postoperative venous thromboembolism is rare in Asian patients. In the recently reported prospective epidemiological study of Asian patients undergoing orthopedic surgery without receiving thromboprophylaxis (SMART), the rate of symptomatic venous thromboembolism or sudden death, as notified by the investigators, was 2.3% (99% confidence interval [CI]: 1.6-3.2), and 1.2% (28 patients, 99% CI: 0.7-1.8) after adjudication by an independent committee. 1 Chronic heart failure, varicose veins and a history of venous thromboembolism were found to be independent risk factors (p<0.05) for the occurrence of the primary outcome. 1 In a recent review of published studies in Asian patients undergoing surgery and not receiving thromboprophylaxis, the adjusted incidence of total (symptomatic and asymptomatic) deep-vein thrombosis was 13% (95% CI: 10-16) in general surgery, 16% (95% CI: [13] [14] [15] [16] [17] [18] [19] [20] after total hip replacement, 50% (95% CI: 44-55) after total knee replacement, and 18% (95% CI: 12-24) after hip fracture surgery. The adjusted incidence of symptomatic pulmonary embolism was 1% (95% CI: 0-2) in general surgery and 1.4% (95% CI: 1-3) after total hip replacement. 2 Furthermore, it was shown that the incidence of fatal pulmonary embolism had increased over time. 2 Taken together, these results suggest that the risk of venous thromboembolism in Asian patients is significant and that both the risk and pattern of venous thromboembolism are comparable to those reported in Western countries. 3, 4 Asymptomatic venous thromboembolism has long been recognized as a valid surrogate outcome measure for symptomatic venous thromboembolism. 5 However, the rate of post-operative asymptomatic deepvein thrombosis in Asian patients remains uncertain.
As part of the SMART program, we therefore performed a prospective epidemiological study to estimate the rate of venous thromboembolism, including asymptomatic deep-vein thrombosis, in Asian patients undergoing hip or knee surgery and not receiving pharmacological thromboprophylaxis. Venous thromboembolism was assessed by venography, the reference method for detecting deep-vein thrombosis in asymptomatic patients. [5] [6] [7] [8] A secondary objective was to determine risk factors for venous thromboembolism. The recently reported AIDA study was conducted during the same period of time as our study, in different Asian centers, and had a comparable design. 
Design and Methods
This was a prospective, international, multicenter, observational study of a cohort of consecutive Asian patients undergoing total hip or knee replacement. It was conducted in eight centers in three Asian countries: Bangladesh, Korea and Taiwan (see Appendix). None of the participating centers routinely used pharmacological thromboprophylaxis. The SMART Venography Study was conducted according to a parallel protocol of the SMART study, in different patients and centers. 1 
Patients
Asian patients aged at least 40 years old, hospitalized for a first elective total hip or knee replacement, or bilateral total hip or knee replacement if performed during the same intervention, were recruited. Patients scheduled to undergo a revision procedure or total hip or knee replacement following trauma, and those scheduled to receive thromboprophylactic drugs during their hospital stay, i.e. unfractionated heparin, low-molecular-weight heparins, heparinoids, vitamin K antagonists, hirudin, antiplatelet agents or dextran, were to be excluded. Other main exclusion criteria were the use of antiplatelet agents or vitamin K antagonists within the week preceding inclusion, and any contraindication to venography according to the investigator. The use of non-steroidal anti-inflammatory drugs, elastic bandaging, support stockings, and physiotherapy was left to the investigator's discretion.
Study design
Patients were to be systematically examined for deepvein thrombosis by bilateral ascending contrast venography of the lower extremities 10 between days 5 and 14 after surgery. If deep-vein thrombosis was clinically suspected before the planned day of venography, ultrasonography could be performed. This was to be followed by bilateral venography in the event of any persistent doubt on ultrasonography examination. If the ultrasonography was negative, bilateral venography was to be performed on the scheduled day. Clinically suspected pulmonary embolism was to be confirmed by a highprobability lung scan, pulmonary angiography, helical computed tomography, or at autopsy. All venograms were reviewed centrally.
After hospital discharge, patients were contacted, by mail or telephone, 1 month (i.e. between 30 and 37 days) after surgery and asked to report any symptoms or signs of venous thromboembolism, bleeding and re-hospitalization. In the event of venous thromboembolism during the study, treatment was left to the investigator's discretion.
The study was conducted according to the ethical principles stated in the Declaration of Helsinki and local regulations. The protocol was approved by independent ethics committees and written informed consent was obtained before inclusion into the study.
Study outcomes
The primary study outcome was the incidence of the composite of adjudicated confirmed asymptomatic or symptomatic venous thromboembolism (defined as deepvein thrombosis, fatal or non-fatal pulmonary embolism, or both) or sudden death at hospital discharge. Other © F e r r a t a S t o r t i F o u n d a t i o n study outcomes were the composite of venous thromboembolism or sudden death at the 1-month follow-up, and overall mortality at 1-month follow-up. All reported venous thromboembolic events and deaths that occurred during the course of the study were reviewed centrally by a two-member committee. Patient cases were reviewed using data from case report forms, patients' records, ultrasonography reports, venograms, angiograms, scintigrams and all other available additional documentation. Patients with no events were not reviewed. Evaluation of the main study outcomes was based on this central assessment.
Statistical analysis
The number of patients to be included in the study was set at approximately 400. It was calculated that this sample size would allow a precision of about ±4.2% at a level of 95% with an assumed event rate of 25%.
The risks of documented asymptomatic or symptomatic venous thromboembolism and sudden death at hospital discharge and at the 1-month follow-up were analyzed by multiple logistic regression. Univariate analysis was performed to screen potential variables for inclusion in the final multivariate model. The following patient-related and surgical characteristics were recorded at baseline and further tested as potential risk factors for venous thromboembolism or sudden death (primary outcome): age, gender, body-mass index, smoking (current or within the last 5 years), history of cancer or active cancer, family or personal history of venous thromboembolism, known thrombophilia, chronic heart failure, chronic respiratory failure, varicose veins, hormone therapy (i.e. estrogen, hormone replacement and anti-androgen therapy) within 1 week before surgery, time between admission and surgery, type of surgery, duration of surgery, type of anesthesia, concomitant treatment, duration of immobilization, and duration of hospital stay. Variables that were significant at the 0.10 level in the univariate analysis were included in the multivariate logistic regression analysis. Variables significant at the 0.05 level in the Wald χ 2 test in the final multivariate analysis were retained as independent predictive factors. The odds ratio and associated 95% CI for the various potential risk factors were calculated. All analyses were performed using SAS Windows V8 software (SAS Institute, Cary, NC, USA).
Results

Patients' characteristics
Between May 2002 and January 2004, 393 patients were enrolled. Seven patients were not considered in the final analysis, three because they did not undergo surgery and four because they received anticoagulant treatment within 1 week before surgery. The median age of the patients was 65 years (range: 58-85) and 63.7% of patients were female ( 
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Surgical characteristics and concomitant treatments after surgery
The majority (58.5%) of patients underwent surgery for knee replacement (Tables 1 and 2 ). The median interval from admission to surgery was 2 (range: 0-23) days and the median duration of hospital stay was 7 (range: 3-76) days. Operations were conducted mainly under general anesthesia (77.2% of patients).
From surgery to hospital discharge, graduated compression devices were applied to 32.1% of patients and physiotherapy was provided to 38.6%. Aspirin and nonsteroidal anti-inflammatory drugs were administered to 2.1% and 80.3% of patients, respectively. Unfractionated heparin, low-molecular-weight heparin and/or vitamin K antagonists were given to 3.6% of patients. Most patients (99.2%) received antibiotics.
Venous thromboembolic events until hospital discharge
Venography was performed in 348 (90.2%) patients from 3 to 22 days after surgery (median: 7 days). The main reasons for not performing venography were patient withdrawal from the study (n=12) and patient refusal (n=12). All venograms were reviewed centrally, and 326 (84.5%) were considered to be evaluable. Among these, 272 (83.4%) were performed between days 5 and 14 after surgery (as planned), 47 were performed before day 5 (44 on day 4 and 3 on day 3), and 7 after day 14 (6 on day 15 and one on day 22).
The rate of the composite of adjudicated asymptomatic or symptomatic venous thromboembolism or sudden death up to hospital discharge was 36.5% (119 patients, 99% CI: 29.7-43.7; Table 3 ). The rate of symptomatic venous thromboembolism, all events corresponding to episodes of deep-vein thrombosis, was 0.9% (three patients, 99% CI: 0.1-3.3). Both distal deep-vein thrombosis and proximal deep-vein thrombosis occurred more frequently in patients undergoing total knee replacement than in those undergoing total hip replacement.
Clinical events up to one month
Overall, 92.7% of patients (n=358) were followed up for a median of 33 (range: 5-102) days after surgery; 14 patients were lost to follow-up, 13 patients withdrew consent and one patient died.
From discharge to the end of follow-up, two additional episodes of adjudicated symptomatic venous thromboembolism occurred. One patient, who underwent a knee replacement, presented with asymptomatic distal deep-vein thrombosis at day 4, experienced a symptomatic deep-vein thrombosis during follow-up. In addition, one patient who had a hip replacement experienced a pulmonary embolism. The rate of the composite of adjudicated symptomatic venous thromboembolism or sudden death at the 1-month follow-up was 1.5% (5/323 patients; 99% CI: 0.3-4.3). Overall, 1.9% (6/322) of patients were re-admitted to hospital during the follow-up.
Risk factors for symptomatic venous thromboembolism or sudden death
Among baseline and surgical characteristics of patients, and risk factors previously identified in Western patients, 3, 4 age, gender, smoking habit, obesity (a body mass index of more than 30 kg/m 2 ), knee replacement surgery, duration of surgery, treatment with antibiotics within 1 week before surgery, and duration of hospital 
Discussion
This study is one of the largest epidemiological studies conducted in Asian patients to evaluate the rate of venous thromboembolism after hip or knee replacement surgery, including asymptomatic deep-vein thrombosis. We used bilateral venography, the gold standard for detecting deep-vein thrombosis in asymptomatic patients. [5] [6] [7] In addition, as in modern large Western studies, all venograms were reviewed centrally. The proportion of evaluable patients (84.5%) was high compared with the percentages of patients evaluable for primary efficacy (69.0 to 82.0%) recently reported in large multicenter studies using venography in orthopedic surgery, [11] [12] [13] [14] [15] [16] and the vast majority of patients (92.7%) underwent clinical follow-up. We found a rate of asymptomatic or symptomatic venous thromboembolism or sudden death (primary outcome) of 36.5% (99% CI: 29.7-43.7) and a rate of proximal deep-vein thrombosis of 9.8% at hospital discharge. Both the primary outcome and proximal deep-vein thrombosis occurred more frequently in patients undergoing knee replacement surgery (50.0% and 14.1%, respectively) than in those undergoing hip replacement surgery (17.2% and 3.7%, respectively). Besides knee replacement surgery, duration of surgery was identified as an independent risk factor for venous thromboembolism at hospital discharge, as was treatment with antibiotics within 1 week before surgery. The latter finding was unexpected and may be related to chance as we could not conceive any obvious relationship between the prevention of infection and post-operative venous thromboembolism. It is worth noting that these high rates of events were observed in a study population with a low risk profile for venous thromboembolism. First, patients scheduled to receive thromboprophylaxis were excluded from our study. In addition, only 15.4% of patients were obese and none reported a previous history of venous thromboembolism compared with approximately 26% and 4.5%, respectively, in recent studies performed in Western patients undergoing orthopedic surgery. 17 Thus, it is likely that the venous thromboembolism rates observed in our study represent a conservative estimate of the true rates in Asian patients undergoing hip or knee replacement without receiving thromboprophylaxis.
In previous Asian epidemiological studies, the rate of systematically detected deep-vein thrombosis varied considerably, ranging from 0 to 64.3% after hip replacement surgery and from 11.3% to 76.5% after knee replacement surgery. 1 However, the majority of these studies were small in size and some used unilateral venography of the operated leg or ultrasonography, creating uncertainty as to the actual rate of asymptomatic deep-vein thrombosis in these settings. The more recent AIDA study was conducted in 407 Asian patients undergoing orthopedic surgery in six Asian countries and used bilateral venography to screen for asymptomatic deep-vein thrombosis 6-10 days after surgery, with central adjudication of venograms. 9 Its results were very similar to ours, with a . In a recent study in Taiwan conducted on three groups of patients receiving either nadroparin, indomethacin or no treatment, and undergoing bilateral venography up to 7 days after total knee arthroplasty, the rates of total and proximal deep-vein thrombosis in the control group were 71% and 5.9%, respectively. 18 In another study conducted in Singapore on 149 patients undergoing total knee arthroplasty, the rate of proximal deep-vein thrombosis detected by ultrasonography performed on post-operative day 5 or 6 was 4.7%. 19 Our results are remarkably consistent with those obtained in the above-mentioned studies, conducted during the same period of time in different centers and countries, and unequivocally indicate that asymptomatic venous thromboembolism occurs frequently after orthopedic surgery in Asian patients, at rates similar to those reported in Western patients (42-57% and 41-85% for hip and knee replacement surgery, respectively), 3, 4 at least with respect to knee replacement surgery. In our study, the rate of symptomatic venous thromboembolism or sudden death was 0.9% at hospital discharge and 1.5% at 1 month follow-up. Again, previous small epidemiological studies performed in Asian patients undergoing major orthopedic surgery, and using different designs and confirmatory diagnostic tools, gave disparate results with rates of symptomatic events ranging from 0.0% to 47.1%. [20] [21] [22] [23] [24] [25] However, in the recently reported large epidemiological study in 2420 Asian patients (11 Asian countries) undergoing major orthopedic surgery (SMART), the rates of the composite of adjudicated confirmed symptomatic venous thromboembolism or sudden death were 1.2% (99% CI: 0.7-1.8) up to hospital discharge and 1.5% (99% CI: 1.0-2.3) at 1 month, 2 which are similar to those found in our study. Recent data regarding the rate of symptomatic events in Western patients undergoing orthopedic surgery without receiving thromboprophylaxis are limited. In one study, however, symptomatic events were reported in 1.2% of such patients, 10 days after surgery, 26 a rate close to those reported in Asian patients in the SMART study and in the present study. As in AIDA and SMART, very few symptomatic events occurred after hospital discharge, in contrast to rates ranging from 2.7 to 4.3% in Western patients during the month following 1 week of thromboprophylaxis. [27] [28] [29] [30] Treatment of asymptomatic deep-vein thrombosis based on the local site assessment of venography may have modified the natural history of the disease, preventing the occurrence of symptomatic events after discharge. 9 Lack of awareness of clinical symptoms in Asian patients may also contribute to this discrepancy. 2 In conclusion, without pharmacological thromboprophylaxis, the incidence of asymptomatic and symptomatic venous thromboembolism after major orthopedic surgery in Asian patients is high. These results suggest that thromboprophylaxis should be considered in this context. To our knowledge, only five small open studies have evaluated a prophylactic method in Asian patients. 18, [31] [32] [33] [34] These studies were small in size and the beneficial effect of treatment was in general not statistically significant, but all showed that prophylaxis could reduce the rate of venous thromboembolism to some extent. Although these data should be confirmed in larger well-conducted multicenter studies, we believe that there is no reason why the benefit of thromboprophylaxis, well documented in the West, 4 should not also be achieved in Asian patients.
